United Therapeutics Corporation (NASDAQ:UTHR) Given Average Rating of “Moderate Buy” by Brokerages

United Therapeutics Corporation (NASDAQ:UTHR) has been given an average recommendation of “Moderate Buy” by the eleven brokerages that are covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $509.50.

UTHR has been the topic of several recent analyst reports. HC Wainwright increased their target price on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Royal Bank Of Canada upped their price objective on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. UBS Group boosted their target price on United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Finally, Wells Fargo & Company upped their price target on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th.

Insider Activity

In related news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction on Monday, November 17th. The shares were sold at an average price of $470.43, for a total transaction of $10,584,675.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In the last ninety days, insiders have sold 542,214 shares of company stock valued at $260,031,533. Corporate insiders own 10.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Torren Management LLC purchased a new position in shares of United Therapeutics during the fourth quarter worth about $26,000. Activest Wealth Management raised its stake in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. Entrust Financial LLC acquired a new stake in United Therapeutics during the 4th quarter worth approximately $31,000. Wilmington Savings Fund Society FSB grew its stake in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. purchased a new position in shares of United Therapeutics in the 4th quarter valued at approximately $48,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Stock Up 1.3%

Shares of United Therapeutics stock opened at $485.36 on Tuesday. United Therapeutics has a 52-week low of $266.98 and a 52-week high of $519.99. The company has a market capitalization of $20.90 billion, a P/E ratio of 18.39, a P/E/G ratio of 2.58 and a beta of 0.85. The company has a 50 day moving average of $486.75 and a 200 day moving average of $427.47.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.